Favorable effects of flecainide in transvenous internal cardioversion of atrial fibrillation

Journal of the American College of Cardiology

Volumn 33, Issue 2, 1999, Pages 333-341

  Boriani, Giuseppe ^a   Biffi, Mauro ^a   Capucci, Alessandro ^a   Bronzetti, Gabriele ^a   Ayers, Gregory M ^b   Zannoli, Romano ^a   Branzi, Angelo ^a   Magnani, Bruno ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b BOSTON SCIENTIFIC CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLECAINIDE;

ADULT; AGED; ANTIARRHYTHMIC ACTIVITY; ARTICLE; BRADYCARDIA; CARDIOVERSION; CLINICAL ARTICLE; CONTROLLED STUDY; DEFIBRILLATION; DRUG EFFICACY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL;

ADULT; AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CHRONIC DISEASE; ELECTRIC COUNTERSHOCK; ELECTROCARDIOGRAPHY; FEMALE; FLECAINIDE; FOLLOW-UP STUDIES; HEART ATRIA; HEART CATHETERIZATION; HEART RATE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 0033081933     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00577-4     Document Type: Article

References (46)

1. Alt E., Schmitt C., Ammer R., et al. Initial experience with intracardiac atrial defibrillation in patients with chronic atrial fibrillation. Pacing Clin Electrophysiol. 17:1994;1067-1078.
2. Murgatroyd F.D., Slade A.K.B., Sopher S.M., Rowland E., Ward D.E., Camm A.J. Efficacy and tolerability of transvenous low energy cardioversion of paroxysmal atrial fibrillation in humans. J Am Coll Cardiol. 25:1995;1347-1353.
3. Levy S., Ricard P., Lau C.P., et al. Multicenter low energy transvenous atrial defibrillation (XAD) trial results in different subsets of atrial fibrillation. J Am Coll Cardiol. 29:1997;750-755.
4. Cooper R.A.S., Alferness C.A., Smith W.M., Ideker R.E. Internal cardioversion of atrial fibrillation in sheep. Circulation. 87:1993;1673-1686.
5. Ayers G.M., Alferness C.A., Ilina M., et al. Ventricular proarrhythmic effects of ventricular cycle length and shock strength in a sheep model of transvenous atrial defibrillation. Circulation. 89:1994;413-422.
6. Sopher S.M., Murgatroyd F.D., Slade A.K.D., et al. Low energy internal cardioversion of atrial fibrillation resistant to transthoracic shocks. Heart. 75:1996;635-638.
7. Schmitt C., Alt E., Plewan A., et al. Low energy intracardiac cardioversion after failed conventional external cardioversion of atrial fibrillation. J Am Coll Cardiol. 28:1996;994-999.
8. Rossi M., Lown B. The use of quinidine in cardioversion. Am J Cardiol. 19:1967;234-238.
9. Szekely P., Wynne N.A., Pearson D.T., Batson G.A., Sidens D.A. Direct current shock and antidysrhythmic drugs. Br Heart J. 32:1970;209-218.
10. Van Gelder I.C., Crijns H.J., Van Gilst W.H., De Lagen C.D., Van Wijk L.M., Like I. Effects of flecainide on the atrial defibrillation threshold. Am J Cardiol. 63:1989;112-116.
11. Sagristà-Sauleda J., Permanyer-Miralda G., Soler-Soler J. Electrical cardioversion after amiodarone administration. Am Heart J. 123:1992;1536-1542.
12. Bianconi L., Mennuni M., Lukic V., Castro A., Chieffi M., Santini M. Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation a placebo-controlled study. J Am Coll Cardiol. 28:1996;700-706.
13. Szyska A., Baszynska-Wachoviak H., Cielinski A. Impact of antiarrhythmic premedication on efficacy of electrical cardioversion [abstract]. Eur Heart J. 17 Suppl 490:1996.
14. Lau C.P., Lok N.S. A comparison of transvenous atrial defibrillation of acute and chronic atrial fibrillation and the effect of intravenous sotalol on human atrial defibrillation threshold. Pacing Clin Electrophysiol. 20:1997;2442-2452.
15. Sopher S.M., Camm A.J. Atrial fibrillation maintenance of sinus rhythm versus rate control. Am J Cardiol. 77:1996;24A-37A.
16. Laupacis A., Albers G., Dalen J., Dunn M., Feinberg W., Jacobson A. Antithrombotic therapy in atrial fibrillation. Chest. 108:1995;352S-359S.
17. Capucci A., Biffi M., Boriani G., et al. Dynamic electrophysiologic behavior of human atria during paroxysmal atrial fibrillation. Circulation. 92:1995;1193-1202.
18. Coxon R.E., Hodgkinson A.J., Sidki A.M., Landon J., Gallacher G. Development of fluoroimmunoassays for flecainide. Ther Drug Monit. 9:1987;478-483.
19. Holmes B., Heel R.C. Flecainide a preliminary review of its pharmacokinetic properties and therapeutic efficacy. Drugs. 29:1985;1-33.
20. Baker B.M., Botteron G.W., Ambos H.D., Ayers G.M., Smith J.M. The effect of amiodarone, sotalol, and procainamide on internal atrial defibrillation threshold [abstract]. Circulation. 92:1995;I-473.
21. Uno K., Kumagai K., Khrestian C., Ayers G.M., Waldo A.L. Effects of flecainide on atrial defibrillation thresholds and ventricular vulnerability during delivery of low-energy atrial shocks in the canine sterile pericarditis model [abstract]. Circulation. 94 Suppl I:1996;I-68.
22. Capucci A., Lenzi T., Boriani G., et al. Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without structural heart disease or with only systemic hypertension. Am J Cardiol. 70:1992;69-72.
23. Boriani G., Biffi M., Capucci A., et al. Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease. Ann Intern Med. 126:1997;621-625.
24. Donovan K.D., Dobb G.J., Coombs L.J., et al. Efficacy of flecainide for the reversion of acute onset atrial fibrillation. Am J Cardiol. 70:1992;50A-55A.
25. the Flecainide Supraventricular Tachycardia Study Group , Anderson J.L., Gilbert E.M., Alpert B.L., et al. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy a multi-center double-blind crossover study of flecainide and placebo with transtelephonic monitoring. Circulation. 80:1989;1557-1570.
26. Pritchett E.L., McCarthy E.A., Wilkinson W.E. Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias a randomized placebo-controlled crossover trial in patients tolerating oral therapy. Ann Intern Med. 114:1991;539-544.
27. Fain E.S., Dorian P., Davy J.M., Kates R.E., Winkle R.A. Effects of encainide and its metabolites on energy requirements for defibrillation. Circulation. 73:1986;1334-1341.
28. Hernandez R., Mann D.E., Breckinridge S., Williams G., Reiter M.J. Effects of flecainide on defibrillation thresholds in the anesthetized dog. J Am Coll Cardiol. 14:1989;777-781.
29. Peters W., Gang E.S., Okazaki H., et al. Acute effects of intravenous propafenone on the internal ventricular defibrillation threshold in the anesthetized dog. Am Heart J. 122:1991;1355-1360.
30. Natale A., Montenero A.S., Bombardieri G., et al. Effects of acute and prolonged administration of propafenone on internal defibrillation in the pig. Am Heart J. 124:1992;104-109.
31. Farré J., Asso A., Romero J., et al. Antiarrhythmic drugs in patients with an automatic implantable defibrillator. Pacing Clin Electrophysiol. 18:1995;579-591.
32. Guarnieri T., Tomaselli G., Griffith L.S.C., Brinker J. The interaction of antiarrhythmic drugs and the energy for cardioversion of chronic atrial fibrillation. Pacing Clin Electrophysiol. 14:1991;1007-1012.
33. Capucci A., Biffi M., Boriani G., et al. Therapeutic implications of 1C drugs in paroxysmal atrial fibrillation by the light of electrophysiologic profile [abstract]. Eur Heart J. 13 Suppl:1992;211.
34. Rensma P.L., Allessie M.A., Lammers W.E.J.P., Bonke F.I.M., Schalij M.J. The length of excitation wave as an index for the susceptibility to reentrant atrial arrhythmias. Circ Res. 62:1988;395-410.
35. Allessie M.A., Konings K., Kirchhof C.J.H.J., Wijffels M. Electrophysiologic mechanisms of perpetuation of atrial fibrillation. Am J Cardiol. 77:1996;10A-23A.
36. Kirchhoff C., Wijffels M., Brugada J., Planellas J., Allessie M. Mode of action of a new class IC drug (ORG 7797) against atrial fibrillation in conscious dogs. J Cardiovasc Pharmacol. 17:1991;116-124.
37. Wang Z., Page P., Nattel S. Mechanism of flecainide's antiarrhythmic action in experimental atrial fibrillation. Circ Res. 71:1992;271-287.
38. Wells J.L., Karp R.B., Kouchoukos N.T., MacLean W.A.H., James T.N., Waldo A.L. Characterisation of atrial fibrillation in man studies following open heart surgery. Pacing Clin Electrophysiol. 1:1978;426-438.
39. Wang Z., Pelletier L.C., Talajic M., Nattel S. Effects of flecainide and quinidine on human atrial action potentials. Circulation. 82:1990;274-283.
40. Van Gelder I.C., Crijns H.J., Van Gilst W.H., Verwer R., Lie K.I. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation or flutter. Am J Cardiol. 68:1991;41-46.
41. Levy S., Camm J. An implantable atrial defibrillator an impossible dream? Circulation. 87:1993;1769-1772.
42. Boriani G., Biffi M., Bronzetti G., et al. Efficacy and tolerability in fully conscious patients of transvenous low energy internal atrial cardioversion for atrial fibrillation. Am J Cardiol. 81:1998;241-244.
43. Falk R.H. Proarrhythmia in patients treated for atrial fibrillation or flutter. Ann Intern Med. 117:1992;141-150.
44. Bennett M.A., Pentecost B.L. The pattern of onset and spontaneous cessation of atrial fibrillation in man. Circulation. 41:1970;981-988.
45. Lok N.S., Lau C.P., Tang Y.W. Variation of defibrillation threshold in repeated transvenous atrial defibrillation [abstract]. Pacing Clin Electrophysiol. 18:1995;850.
46. Santini M., Pandozi C., Toscano S., et al. Changes in intracardiac atrial cardioversion at rest and during exercise. J Am Coll Cardiol. 29:1997;576-581.